Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Failure: Strength in Devices

Executive Summary

With the aging of the population, heart failure has emerged as a key public health concern. Several device-based technologies are poised to positively impact both ends of the disease spectrum, enabling earlier diagnosis and treatment, and providing more treatment options for those in later stages of the disease.

You may also be interested in...



Cardiac Assist: Pumping up the Heart Failure Market

After struggling for years to gain momentum, the ventricular assist device market appears finally to be coming of age. Second-generation VAD designs are performing well and seem to have largely addressed the pump durability and safety issues of the past that stymied growth and prevented this market from reaching its full potential. In the process, these new pumps, and their third-generation counterparts now waiting in the wings, are revitalizing interest in VADs among both physicians and patients, and propelling this potential multibillion dollar market to the forefront once again.

Berlin Heart: Starting Over

After cutting his teeth on heart pump technology at re-start Impella, Rolf Kaese thought he had found the perfect vehicle to build a ventricular assist device business at Berlin Heart. But now Kaese is starting over and so is Berlin Heart after a falling out between the two, in a tale that's an object lesson to anyone who's ever had to begin again.

Paracor: Can a Mechanical Device Treat Heart Failure?

Heart failure is a huge growing market in which devices are looking to succeed where drugs have provided only limited benefit. Paracor is taking on the role of David In a field dominated by the Goliaths in cardiac rhythm management and their powered devices. The company is betting that its strategy to focus first on a mechanical approach offers a better alternative for many patients not well-served by current therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT035100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel